Fariba Mozaffari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Fariba Mozaffari has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
Anders Österborg
Department of Oncology-Pathology, Immune and Gene therapy Lab, Cancer Center Karolinska (CCK), Karolinska University Hospital Solna and Karolinska Institute, Stockholm, Sweden
8 shared publicationsAniruddha Choudhury
Center for Immune and Targeted Therapy Greenslopes Private Hospital
5 shared publications- Håkan Mellstedt
Department of Oncology-Pathology, Immune and Gene therapy Lab, Cancer Center Karolinska (CCK), Karolinska University Hospital Solna and Karolinska Institute, Stockholm, Sweden
5 shared publications - Lotta Hansson
Department of Hematology, Karolinska University Hospital, Stockholm, Sweden
5 shared publications Shahryar Kiaii
Institute of Cancer, Barts and The London School of Medicine and Dentistry, Charterhouse Square, London, EC1M 6BQ, UK
4 shared publicationsEva Rossmann
Departments of Hematology and Oncology Karolinska University Hospital Stockholm Sweden
3 shared publications
Latest Publications
- 23 March 2018
- Published by Wiley in European Journal of Haematology
- Vol. 101 (1) , 68-77
Lenalidomide as immune adjuvant to a dendritic cell vaccine in chronic lymphocytic leukemia patients
Objectives: We previously showed that immunization with ex vivo‐ generated autologous dendritic cells loaded with apoptotic tumor cells (Apo‐DC) potentiated tumor‐specific immunity in chronic lymphocytic leukemia (CLL) patients. Here, we evaluated safety and immunogenicity of Apo‐DC in combination with lenalidomide, granulocyte‐macrophage colony‐stimulating factor (GM‐CSF), and low‐dose cyclophosphamide (CTX).Methods: Ten previously untreated patients with slowly progressing CLL received 5 Apo‐DC vaccinations and lenalidomide orally for 24 weeks either alone (cohort I, n = 5) or together with subcutaneous GM‐CSF and intravenous CTX (cohort II, n = 5). Tumor‐specific T‐cell responses were measured by proliferation and IFN‐γ ELISPOT assays. Immune monitoring was performed by flow cytometry.Results: Dose‐limiting toxicity was observed in 3/10 patients, 2 in cohort I and one in cohort II. One patient developed autoimmune hemolytic anemia and another grade 4 thrombocytopenia. Vaccine‐induced immune responses were seen in 5/5 and 4/5 patients in cohort I and II, respectively. The expression of immune checkpoints on T cells did not change significantly.Conclusions: Lenalidomide alone or in combination with GM‐CSF and low‐dose CTX as immune adjuvant to the Apo‐DC vaccine elicited tumor‐specific T‐cell responses in CLL patients. However, unexpected toxicity was observed and caution is suggested in further exploring this drug as immune adjuvant in CLL.
- 23 March 2018
- Published by Wiley in European Journal of Haematology
- Vol. 101 (1) , 68-77
Lenalidomide as immune adjuvant to a dendritic cell vaccine in chronic lymphocytic leukemia patients
Objectives: We previously showed that immunization with ex vivo‐ generated autologous dendritic cells loaded with apoptotic tumor cells (Apo‐DC) potentiated tumor‐specific immunity in chronic lymphocytic leukemia (CLL) patients. Here, we evaluated safety and immunogenicity of Apo‐DC in combination with lenalidomide, granulocyte‐macrophage colony‐stimulating factor (GM‐CSF), and low‐dose cyclophosphamide (CTX).Methods: Ten previously untreated patients with slowly progressing CLL received 5 Apo‐DC vaccinations and lenalidomide orally for 24 weeks either alone (cohort I, n = 5) or together with subcutaneous GM‐CSF and intravenous CTX (cohort II, n = 5). Tumor‐specific T‐cell responses were measured by proliferation and IFN‐γ ELISPOT assays. Immune monitoring was performed by flow cytometry.Results: Dose‐limiting toxicity was observed in 3/10 patients, 2 in cohort I and one in cohort II. One patient developed autoimmune hemolytic anemia and another grade 4 thrombocytopenia. Vaccine‐induced immune responses were seen in 5/5 and 4/5 patients in cohort I and II, respectively. The expression of immune checkpoints on T cells did not change significantly.Conclusions: Lenalidomide alone or in combination with GM‐CSF and low‐dose CTX as immune adjuvant to the Apo‐DC vaccine elicited tumor‐specific T‐cell responses in CLL patients. However, unexpected toxicity was observed and caution is suggested in further exploring this drug as immune adjuvant in CLL.
- Open Access
- 12 November 2015
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (11) , e0142310
Spontaneous Immunity Against the Receptor Tyrosine Kinase ROR1 in Patients with Chronic Lymphocytic Leukemia
ROR1 is a receptor tyrosine kinase expressed in chronic lymphocytic leukemia (CLL) and several other malignancies but absent in most adult normal tissues. ROR1 is considered an onco-fetal antigen. In the present study we analysed spontaneous humoral and cellular immunity against ROR1 in CLL patients. Antibodies against ROR1 were analysed in 23 patients and 20 healthy donors by ELISA and Western blot. Purified serum IgG from patients was tested for cytotoxicity against CLL cells using the MTT viability assay. A cellular immune response against ROR1 derived HLA-A2 restricted 9 aa and 16 aa long peptides were analysed using peptide loaded dendritic cells co-cultured with autologous T cells from CLL patients (n = 9) and healthy donors (n = 6). IFN-γ, IL-5 and IL-17A-secreting T cells were assessed by ELISPOT and a proliferative response using a H3-thymidine incorporation assay. The majority of CLL patients had antibodies against ROR1. Significantly higher titers of anti-ROR1 antibodies were noted in patients with non-progressive as compared to progressive disease. The extracellular membrane-close ROR1 KNG domain seemed to be an immunodominant epitope. Ten patients with high titers of anti-ROR1 binding antibodies were tested for cytotoxicity. Five of those had cytotoxic anti-ROR1 antibodies against CLL cells. ROR1-specific IFN-γ and IL-17A producing T cells could be detected in CLL patients, preferentially in non-progressive as compared to patients with progressive disease (p<0.05). ROR1 seemed to spontaneously induce a humoral as well as a T cell response in CLL patients. The data support the notion that ROR1 might be a specific neo-antigen and may serve as a target for immunotherapy.
- 12 November 2015
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (11) , e0142310
Open AccessSpontaneous Immunity Against the Receptor Tyrosine Kinase ROR1 in Patients with Chronic Lymphocytic Leukemia
ROR1 is a receptor tyrosine kinase expressed in chronic lymphocytic leukemia (CLL) and several other malignancies but absent in most adult normal tissues. ROR1 is considered an onco-fetal antigen. In the present study we analysed spontaneous humoral and cellular immunity against ROR1 in CLL patients. Antibodies against ROR1 were analysed in 23 patients and 20 healthy donors by ELISA and Western blot. Purified serum IgG from patients was tested for cytotoxicity against CLL cells using the MTT viability assay. A cellular immune response against ROR1 derived HLA-A2 restricted 9 aa and 16 aa long peptides were analysed using peptide loaded dendritic cells co-cultured with autologous T cells from CLL patients (n = 9) and healthy donors (n = 6). IFN-γ, IL-5 and IL-17A-secreting T cells were assessed by ELISPOT and a proliferative response using a H3-thymidine incorporation assay. The majority of CLL patients had antibodies against ROR1. Significantly higher titers of anti-ROR1 antibodies were noted in patients with non-progressive as compared to progressive disease. The extracellular membrane-close ROR1 KNG domain seemed to be an immunodominant epitope. Ten patients with high titers of anti-ROR1 binding antibodies were tested for cytotoxicity. Five of those had cytotoxic anti-ROR1 antibodies against CLL cells. ROR1-specific IFN-γ and IL-17A producing T cells could be detected in CLL patients, preferentially in non-progressive as compared to patients with progressive disease (p<0.05). ROR1 seemed to spontaneously induce a humoral as well as a T cell response in CLL patients. The data support the notion that ROR1 might be a specific neo-antigen and may serve as a target for immunotherapy.
- 11 June 2014
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 45 (3) , 1293-1303
Telomerase (GV1001) vaccination together with gemcitabine in advanced pancreatic cancer patients
Spandidos Publications is a scientific publisher with a long-standing international reputation for excellent standards and high quality science publications
- 11 June 2014
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 45 (3) , 1293-1303
Telomerase (GV1001) vaccination together with gemcitabine in advanced pancreatic cancer patients
Spandidos Publications is a scientific publisher with a long-standing international reputation for excellent standards and high quality science publications
- Open Access
- 9 October 2012
- Published by Wiley in British Journal of Haematology
- Vol. 159 (5) , 608-12
Phase I study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukaemia: maintaining immune functions during therapy‐induced immunosuppression
- 9 October 2012
- Published by Wiley in British Journal of Haematology
- Vol. 159 (5) , 608-12
Open AccessPhase I study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukaemia: maintaining immune functions during therapy‐induced immunosuppression
- 27 June 2012
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 62 (1) , 51-63
T cells from indolent CLL patients prevent apoptosis of leukemic B cells in vitro and have altered gene expression profile
T cells may have a role in sustaining the leukemic clone in chronic lymphocytic leukemia (CLL). In this study, we have examined the ability of T cells from CLL patients to support the survival of the leukemic B cells in vitro. Additionally, we compared global gene expression of T cells from indolent CLL patients with healthy individuals and multiple myeloma (MM) patients. Apoptosis of purified leukemic B cells was inhibited in vitro when co-cultured with increasing numbers of autologous T cells (p < 0.01) but not autologous B and T cells of normal donors. The anti-apoptotic effect exceeded that of the anti-apoptotic cytokine IL-4 (p = 0.002) and was greater with CD8+ cells (p = 0.02) than with CD4+ cells (p = 0.05). The effect was depended mainly on cell–cell contact although a significant effect was also observed in transwell experiments (p = 0.05). About 356 genes involved in different cellular pathways were deregulated in T cells of CLL patients compared to healthy individuals and MM patients. The results of gene expression profiling were verified for 6 genes (CCL4, CCL5 (RANTES), XCL1, XCL2, KLF6, and TRAF1) using qRT–PCR and immunoblotting. Our results demonstrate that CLL-derived T cells can prevent apoptosis of leukemic B cells and have altered expression of genes that may facilitate the survival of the leukemic clone.
- 27 June 2012
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 62 (1) , 51-63
T cells from indolent CLL patients prevent apoptosis of leukemic B cells in vitro and have altered gene expression profile
T cells may have a role in sustaining the leukemic clone in chronic lymphocytic leukemia (CLL). In this study, we have examined the ability of T cells from CLL patients to support the survival of the leukemic B cells in vitro. Additionally, we compared global gene expression of T cells from indolent CLL patients with healthy individuals and multiple myeloma (MM) patients. Apoptosis of purified leukemic B cells was inhibited in vitro when co-cultured with increasing numbers of autologous T cells (p < 0.01) but not autologous B and T cells of normal donors. The anti-apoptotic effect exceeded that of the anti-apoptotic cytokine IL-4 (p = 0.002) and was greater with CD8+ cells (p = 0.02) than with CD4+ cells (p = 0.05). The effect was depended mainly on cell–cell contact although a significant effect was also observed in transwell experiments (p = 0.05). About 356 genes involved in different cellular pathways were deregulated in T cells of CLL patients compared to healthy individuals and MM patients. The results of gene expression profiling were verified for 6 genes (CCL4, CCL5 (RANTES), XCL1, XCL2, KLF6, and TRAF1) using qRT–PCR and immunoblotting. Our results demonstrate that CLL-derived T cells can prevent apoptosis of leukemic B cells and have altered expression of genes that may facilitate the survival of the leukemic clone.
- Open Access
- 16 November 2008
- Published by American Society of Hematology in Blood
- Vol. 112 (11) , 2071
T Cells from Patients with Chronic Lymphocytic Leukaemia Prevent Apoptosis of Autologous CLL Cells in a Dose- and Cell:Cell-Contact Dependent Fashion; Rationale for New Therapeutic Possibilities.
Background: Multiple T cell abnormalities in Chronic Lymphocytic Leukemia (CLL) patients are well established. Compared to healthy individuals, total T lymphocyte count, CD8+ cells and CD4+ cells in CLL patients are increased and follow disease activity, i.e. increase at CLL progression. Major alterations in T cell functions and TCR repertoire have also been reported as well as T cells specifically recognizing the leukemic CLL cells. It may be hypothesized that aberrantly functioning T cells contribute to a microenvironment which may allow CLL cells to avoid apoptosis and/or support the proliferative capacity. However, the underlying mechanisms are largely unknown. Materials and Methods: T cells and CLL cells were highly purified from PBMC of 20 patients with indolent CLL as well as normal blood B- and T-cells from healthy control donors (n=7). Autologous T cells and B cells were co-cultured at different T:B ratios for 72 h in ordinary and transwell plates. Apoptosis of B cells were assayed using Annexin-V and supernatants were analysed by Luminex for the following cytokines: RANTES, IL-10, IL-8, TNF-α, IFN-γ, IL-4, MCP-1, CD40L and GM-CSF. Results: Apoptosis of CLL cells was significantly (p<0.01) prevented by autologous T cells in a cell-dose-dependent fashion; the highest rate of apoptosis was observed when CLL cells were cultured alone in the absence of T cells. When the experiments were repeated in transwell plates the apoptosis-inhibiting effect of the T cells was completely ameliorated. No corresponding effects were observed when T cells were co-cultured with normal B cells of healthy donors. Luminex analysis revealed that the levels of IL-4, RANTES, MCP-1, TNF-α and IFN-γ were significantly higher in CLL co-culture experiments (especially at high T:B ratios) as compared to CLL cells alone. Conclusions: Our data provide proof-of-principle that autologous T cells prevent apoptosis of CLL cells in a dose-dependent fashion and the effect was critically dependent on cell:cell contact. A number of cytokine candidates were identified for further studies. The results provide a basis for exploring therapeutic approaches aiming at selective inhibition/depletion of T cells in patients with CLL.
- 16 November 2008
- Published by American Society of Hematology in Blood
- Vol. 112 (11) , 2071
Open AccessT Cells from Patients with Chronic Lymphocytic Leukaemia Prevent Apoptosis of Autologous CLL Cells in a Dose- and Cell:Cell-Contact Dependent Fashion; Rationale for New Therapeutic Possibilities.
Background: Multiple T cell abnormalities in Chronic Lymphocytic Leukemia (CLL) patients are well established. Compared to healthy individuals, total T lymphocyte count, CD8+ cells and CD4+ cells in CLL patients are increased and follow disease activity, i.e. increase at CLL progression. Major alterations in T cell functions and TCR repertoire have also been reported as well as T cells specifically recognizing the leukemic CLL cells. It may be hypothesized that aberrantly functioning T cells contribute to a microenvironment which may allow CLL cells to avoid apoptosis and/or support the proliferative capacity. However, the underlying mechanisms are largely unknown. Materials and Methods: T cells and CLL cells were highly purified from PBMC of 20 patients with indolent CLL as well as normal blood B- and T-cells from healthy control donors (n=7). Autologous T cells and B cells were co-cultured at different T:B ratios for 72 h in ordinary and transwell plates. Apoptosis of B cells were assayed using Annexin-V and supernatants were analysed by Luminex for the following cytokines: RANTES, IL-10, IL-8, TNF-α, IFN-γ, IL-4, MCP-1, CD40L and GM-CSF. Results: Apoptosis of CLL cells was significantly (p<0.01) prevented by autologous T cells in a cell-dose-dependent fashion; the highest rate of apoptosis was observed when CLL cells were cultured alone in the absence of T cells. When the experiments were repeated in transwell plates the apoptosis-inhibiting effect of the T cells was completely ameliorated. No corresponding effects were observed when T cells were co-cultured with normal B cells of healthy donors. Luminex analysis revealed that the levels of IL-4, RANTES, MCP-1, TNF-α and IFN-γ were significantly higher in CLL co-culture experiments (especially at high T:B ratios) as compared to CLL cells alone. Conclusions: Our data provide proof-of-principle that autologous T cells prevent apoptosis of CLL cells in a dose-dependent fashion and the effect was critically dependent on cell:cell contact. A number of cytokine candidates were identified for further studies. The results provide a basis for exploring therapeutic approaches aiming at selective inhibition/depletion of T cells in patients with CLL.
- Open Access
- 1 September 2008
- Published by Elsevier in Annals of Oncology
- Vol. 19 (suppl_7) , vii241-vii247
Overcoming immunosuppressive mechanisms
K. Widén, F. Mozaffari, A. Choudhury, H. Mellstedt; Overcoming immunosuppressive mechanisms, Annals of Oncology, Volume 19, Issue suppl_7, 1 September 2008, Pa
- 1 September 2008
- Published by Elsevier in Annals of Oncology
- Vol. 19 (suppl_7) , vii241-vii247
Open AccessOvercoming immunosuppressive mechanisms
K. Widén, F. Mozaffari, A. Choudhury, H. Mellstedt; Overcoming immunosuppressive mechanisms, Annals of Oncology, Volume 19, Issue suppl_7, 1 September 2008, Pa
- 17 May 2008
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 58 (1) , 111-120
Systemic immune effects of adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide and/or radiotherapy in breast cancer: a longitudinal study
Immunotherapy is being increasingly utilized for adjuvant treatment for breast cancer (BC). We have previously described immune functions during primary therapy for BC. The present study describes immune recovery patterns during long-term, unmaintained follow-up after completion of adjuvant therapy.A group of patients with primary BC had been treated with adjuvant radio-chemotherapy (RT + CT) 5-fluorouracil, epirubicin and cyclophosphamide (FEC) (n = 21) and another group with radiotherapy (RT) (n = 20) alone. Immunological testing of NK and T-cell functions was performed initially at the end of adjuvant treatment and repeated after 2, 6 and 12 months. NK cell cytotoxicity was significantly higher (P < 0.05) at all time-points in patients than in age-matched controls and did not differ between the two treatments groups during one year observation. In contrast, lower numbers of CD4 T-cells and lower expression of CD28 on T-cells was observed particularly in RT + CT patients and did not normalize during the observation period. The numbers of Treg cells (CD4+CD25high) were low in the RT + CT group during follow-up, as well as expression of TCRξ, Zap70, p56lck, P59fyn and PI3 k in CD4+ cells. In contrast, expression of intracellular cytokines (IFN-γ, IL-2, IL-4) in CD4 and CD8 T cells were significantly higher in RT + CT patients than in the RT group and the difference increased during follow-up. In conclusion, NK-cell cytotoxicity increased during unmaintained long-term follow-up whereas CD4 and regulatory T cells as well as signal transduction molecules remained low following adjuvant radio-chemotherapy.
- 17 May 2008
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 58 (1) , 111-120
Systemic immune effects of adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide and/or radiotherapy in breast cancer: a longitudinal study
Immunotherapy is being increasingly utilized for adjuvant treatment for breast cancer (BC). We have previously described immune functions during primary therapy for BC. The present study describes immune recovery patterns during long-term, unmaintained follow-up after completion of adjuvant therapy.A group of patients with primary BC had been treated with adjuvant radio-chemotherapy (RT + CT) 5-fluorouracil, epirubicin and cyclophosphamide (FEC) (n = 21) and another group with radiotherapy (RT) (n = 20) alone. Immunological testing of NK and T-cell functions was performed initially at the end of adjuvant treatment and repeated after 2, 6 and 12 months. NK cell cytotoxicity was significantly higher (P < 0.05) at all time-points in patients than in age-matched controls and did not differ between the two treatments groups during one year observation. In contrast, lower numbers of CD4 T-cells and lower expression of CD28 on T-cells was observed particularly in RT + CT patients and did not normalize during the observation period. The numbers of Treg cells (CD4+CD25high) were low in the RT + CT group during follow-up, as well as expression of TCRξ, Zap70, p56lck, P59fyn and PI3 k in CD4+ cells. In contrast, expression of intracellular cytokines (IFN-γ, IL-2, IL-4) in CD4 and CD8 T cells were significantly higher in RT + CT patients than in the RT group and the difference increased during follow-up. In conclusion, NK-cell cytotoxicity increased during unmaintained long-term follow-up whereas CD4 and regulatory T cells as well as signal transduction molecules remained low following adjuvant radio-chemotherapy.
- 12 June 2007
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 16 (1) , 57-65
Immune response, depression and fatigue in relation to support intervention in mammary cancer patients
To study the effect of support intervention on immune function in breast cancer patients. Breast cancer patients from an ongoing prospective randomised quality-of -life study were chosen for assaying immune functions in relation to a support-group intervention program running on a residential basis. Twenty-one women received adjuvant-combined radio-chemotherapy (CT-RT) and 20 women radiotherapy (RT). Eleven CT-RT and ten RT patients were randomised to support-group intervention, the rest served as controls. Immune tests for NK cells and NK-cell cytotoxicity, as well as lymphocyte subpopulations and response to antigen were performed before intervention, 2, 6, and 12 months later, in parallel to controls and healthy volunteers (n = 11). Depression, anxiety and fatigue were evaluated by the Hospital Anxiety and Depression (HAD) and the Norwegian Fatigue questionnaire. The density of NK cell receptors and in vitro quantitation of functional NK cytotoxicity against K562 cell line were evaluated. Four-colour flow cytometry was used to detect signal transduction molecules and cytokine expression. T-cell proliferate response to purified protein derivate (PPD) antigen was evaluated. No significant immune effect of support intervention could be found. The immune variables were severely disarranged compared to healthy volunteers but showed a statistically significant improvement over time. The majority of patients suffered from fatigue but had low scores for depression and anxiety. No effect on immune parameters could be detected from support intervention. The long-lasting immune suppression might override a putative effect of the intervention. Low depression scores may contribute to the absence of a detectable effect.
- 12 June 2007
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 16 (1) , 57-65
Immune response, depression and fatigue in relation to support intervention in mammary cancer patients
To study the effect of support intervention on immune function in breast cancer patients. Breast cancer patients from an ongoing prospective randomised quality-of -life study were chosen for assaying immune functions in relation to a support-group intervention program running on a residential basis. Twenty-one women received adjuvant-combined radio-chemotherapy (CT-RT) and 20 women radiotherapy (RT). Eleven CT-RT and ten RT patients were randomised to support-group intervention, the rest served as controls. Immune tests for NK cells and NK-cell cytotoxicity, as well as lymphocyte subpopulations and response to antigen were performed before intervention, 2, 6, and 12 months later, in parallel to controls and healthy volunteers (n = 11). Depression, anxiety and fatigue were evaluated by the Hospital Anxiety and Depression (HAD) and the Norwegian Fatigue questionnaire. The density of NK cell receptors and in vitro quantitation of functional NK cytotoxicity against K562 cell line were evaluated. Four-colour flow cytometry was used to detect signal transduction molecules and cytokine expression. T-cell proliferate response to purified protein derivate (PPD) antigen was evaluated. No significant immune effect of support intervention could be found. The immune variables were severely disarranged compared to healthy volunteers but showed a statistically significant improvement over time. The majority of patients suffered from fatigue but had low scores for depression and anxiety. No effect on immune parameters could be detected from support intervention. The long-lasting immune suppression might override a putative effect of the intervention. Low depression scores may contribute to the absence of a detectable effect.